Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 77 citing articles:

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 17
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Mengke Niu, Ming Yi, Ning Li, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 86
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
Diego Kauffmann‐Guerrero, Kathrin Kahnert, Rosemarie Kiefl, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 58
The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors
Na Liu, Jinmei Mao, Peizhi Tao, et al.
Medicine (2022) Vol. 101, Iss. 3, pp. e28617-e28617
Open Access | Times Cited: 42
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N. Donahue, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
Lei Yan, Chengsong Cao, Rui Tang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 49
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
Alice Indini, Erika Rijavec, Francesco Grossi
Cancers (2021) Vol. 13, Iss. 8, pp. 1794-1794
Open Access | Times Cited: 45
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
Edoardo Lenci, Luca Cantini, Federica Pecci, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 1005-1005
Open Access | Times Cited: 38
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Myrto Moutafi, Sandra Martinez-Morilla, Prajan Divakar, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 8, pp. 991-1001
Open Access | Times Cited: 26
Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Kah Yee Goh, Terence You De Cheng, Su Chin Tham, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 508-508
Open Access | Times Cited: 14
Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis
Yan Wang, Qunqin Ni
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 808-819
Open Access | Times Cited: 14
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Anwen Xiong, Jiali Wang, Caicun Zhou
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 31
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer
Airi Fujimoto, Gouji Toyokawa, Yoshimichi Koutake, et al.
Thoracic Cancer (2021) Vol. 12, Iss. 15, pp. 2198-2204
Open Access | Times Cited: 30
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer
Dae Won Kim, Elaine Tan, Junmin Zhou, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 11, pp. 1803-1808
Open Access | Times Cited: 29
Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
Mark Stares, Amanda M. Swan, Kirsten Cumming, et al.
Frontiers in Nutrition (2021) Vol. 8
Open Access | Times Cited: 29
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
Yiming Gao, Zhibo Zhang, Yao Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB
Jia Chen, Sheng Wei, Tianye Zhao, et al.
Disease Markers (2022) Vol. 2022, pp. 1-25
Open Access | Times Cited: 22
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
Deniz Can Güven, Taha Koray Şahin, Enes Erul, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4523-4523
Open Access | Times Cited: 21
Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy
Jerome H. Goldschmidt, Lin‐Na Chou, Philip K. Chan, et al.
Cancer Medicine (2023) Vol. 12, Iss. 22, pp. 20783-20797
Open Access | Times Cited: 12
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy
Lei Wang, Qingzhu Jia, Qian Chu, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2023) Vol. 1, Iss. 1, pp. 18-29
Open Access | Times Cited: 11
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Meng Lu, Jianfang Xu, Ying Ye, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab
Francesco Jacopo Romano, Riccardo Ronga, Francesca Ambrosio, et al.
Cancer Diagnosis & Prognosis (2022) Vol. 3, Iss. 1, pp. 44-52
Open Access | Times Cited: 18
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Yo-Ting Tsai, Julius Strauss, Nicole J. Toney, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004601-e004601
Open Access | Times Cited: 17
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial
Luka Tandarić, Annika Auranen, Katrin Kleinmanns, et al.
Molecular Oncology (2025)
Open Access
Page 1 - Next Page

Scroll to top